Tim Shannon

Intercept's NASH Trial Design Irks Investors news.investors.com/technology/051… #IBDNews via @IBDinvestors - $ICPT $GILD $PCYC $GEVA - need a big swing

Canaan Partners: Don’t Overlook Pharma Customers for Digital-Health Products on.wsj.com/1IptCgF via @WSJ -- nice stuff Julie

Spyryx Biosciences Secures $18 Million in Series A Financing - FierceBiotech: fiercebiotech.com/press-releases… -- Awesome company - important work

The Most Influential Women in Bay Area Business 2015 bizjournals.com/sanfrancisco/m… via @SFBusinessTimes - We always knew it Wende - congrats!!

Digital health companies see data evolution (San Diego Daily Transcript) sddt.com/Technology/art… - Great stuff Julie!!

finance.yahoo.com/news/fda-appro… - the start of pharma back into CV disease

onforb.es/1FLyH3A - great advice from @DeepakKamra

IMS: US prescription drug spending jumped 13 pct. in 2014 finance.yahoo.com/news/ims-us-pr… via @YahooFinance - simply fascinating in many ways

Merck wagers $434M on Arvinas and its protein-disposal system - FierceBiotech: fiercebiotech.com/story/merck-wa… - great companies - I'm biased!

A new cancer drug, made in China on.wsj.com/1BSKZ2B via @WSJ - amazing evolution - pricing will affect world markets with time

School is the Experiment: Self-Directed Learning as a Return to the Way Humans have Evolved to Learn northstarteens.org/school-is-the-… - great stuff

forbes.com/sites/matthewh… - nice story on GBM news and 60 minutes?- does data go to peer reviewed journals anymore? or just social media?

It's Time for Brands to Take Wearables to the Next Level: In an eye-opening talk... bit.ly/1BEDlwU #MPOMMA #sxsw - The future now!!

Biotech’s rally fuels bubble fears on.wsj.com/1FCBICP via @WSJ - is different than 2000 but will pull back with coverage like this

Thomson Reuters Names Most Promising Drugs of 2015 -- prn.to/1Hrd34H - ?? when was last time 3 CV drugs in top 10??

Biotech IPO Performance: Discerning Market Or Rising Tide? onforb.es/1Ha9TlH via @forbes - as always nice work by Bruce!

Tech Is From Mars, Biotech Is From Venus: A Handy Guide To Busting The Jargon onforb.es/18LeBHT via @forbes - Go Julie P!!

Scientists Seek Ban on Method of Editing the Human Genome nyti.ms/19Dizna - Impact on multiple companies founded on Crispr??

Biogen Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s - yhoo.it/1BEB8Np - wow - a golden era for drugs?

Juno stock drops as company projects up to $150M in cash burn in first post-IPO report bit.ly/1FHJVEp -- Investors are surprised??